Click image to enlarge
The V-PLEX SARS-CoV-2 384 Panel 1 (ACE2) Kit is a multiplex neutralization assay that measures the antibodies capable of blocking the binding of angiotensin-converting enzyme 2 (ACE2) to the SARS-CoV-2 Spike and RBD antigens. The Panel serves as a high-throughput alternative to traditional neutralization assays. It includes three (3) important antigens related to SARS-CoV-2: SARS-CoV-2 N, SARS-CoV-2 S1 RBD, and SARS-CoV-2 Spike.
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Analyte(s)
|
|
SARS-CoV-2 N, SARS-CoV-2 S1 RBD, SARS-CoV-2 Spike
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
MESO SECTOR S 600
,
SECTOR Imager 6000
,
MESO SECTOR S 600MM
|
|
|
Plate Type
|
|
384-well
|
|
|
Sample Type
|
|
Serum, Plasma
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Condition
|
|
2-8 °C
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
ACE2 Calibration Reagent
|
2-8 °C
|
1 vial
(65 μL)
|
|
|
|
|
2-8 °C
|
2 vial
(5 plate size)
|
|
|
|
SARS-CoV-2 384 Plate 1
|
2-8 °C
|
5 each
(1 each)
|
|
|
|
|
2-8 °C
|
2 bottle
(200 mL)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
|
RT
|
2 bottle
(100 mL)
|
|
|
|
MSD Blocker A
|
RT
|
1 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
1 bottle
(50 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
ACE2 Calibration Reagent
|
2-8 °C
|
5 vial
(65 μL)
|
|
|
|
|
2-8 °C
|
10 vial
(5 plate size)
|
|
|
|
SARS-CoV-2 384 Plate 1
|
2-8 °C
|
25 each
(1 each)
|
|
|
|
|
2-8 °C
|
10 bottle
(200 mL)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
|
RT
|
10 bottle
(100 mL)
|
|
|
|
MSD Blocker A
|
RT
|
5 bottle
(250 mL)
|
|
|
|
MSD Phosphate Buffer
5X
|
RT
|
5 bottle
(50 mL)
|
|
|
|
Product Inserts
|
|
|
|
Certificate of analysis
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Diagnostic accuracy of the ultrasensitive S-PLEX SARS-CoV-2 N electrochemiluminescence immunoassay
|
|
|
|
IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
|
|
|
|
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
|
|
|
|
Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination
|
|
|
|
SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters